Navigation Links
Companion Animal Vaccines Market: Canine Segment Anticipated to Retain Its Dominance Throughout the Forecast Period: Global Industry Analysis and Opportunity Assessment, 2016-2026
Date:4/19/2017

LONDON, April 19, 2017 /PRNewswire/ --

Companion animal vaccines are used to stimulate an immune response in pets such as canine, avian and feline.

These vaccine products are of various types such as Attenuated Live Vaccines, Conjugate Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, DNA Vaccines and Recombinant Vaccines. Attenuated live vaccines are derived from disease-causing pathogens such as virus or bacteria, which have been weakend under laboratory conditions. Conjugate vaccines are an antigen or toxoid-containing preparation that is linked to polysaccharides and stimulate the immature immune system to defend against the disease-causing organism.


Download the full report: https://www.reportbuyer.com/product/4833633/



Inactivated vaccines are made from microorganisms such as viruses and bacteria that have been killed through physical or chemical processes. Subunit vaccines, like inactivated whole-cell vaccines, do not contain live components of the pathogen. Toxoid vaccines are based on the toxin produced by certain bacteria, which is rendered harmless and used as the antigen in the vaccine to elicit an immune response. DNA vaccines are manufactured by inserting DNA into a bacterial plasmid, which functions as the vector. Recombinant vaccines are produced by genetic engineering technology and use attenuated virus or bacterium as a vector to introduce microbial DNA to the cells of the body.

The global companion animal vaccines market was valued at more than US$ 2,100 Mn in 2015 and is projected to register a CAGR of 6.8% during the forecast period. The market is expected to be valued at nearly US$ 4,500 Mn by the end of 2026.

Global Companion Animal Vaccines Market Forecast, By Species Type, 2016–2026

The Canine species segment is anticipated to register a 6.9% CAGR over the forecast period and be valued at nearly US$ 2,500 Mn by 2026 end. The Canine species segment was estimated to account for 50.9% share of the global companion animal vaccines market by 2016 end. Whereas the Avian species segment was estimated to account for 14.1% value share of the global companion animal vaccines market by 2016 end.

Global Companion Animal Vaccines Market Attractiveness Analysis, By Species Type, 2016–2026

The Canine segment dominated the global companion animal vaccines market in revenue terms in 2016 and is projected to continue to do so throughout the forecast period. The Canine segment is the most attractive segment, recording an attractiveness index of 1.5 over the forecast period. The segment is projected to account for 51.0% value share by 2026 end. The Feline segment is expected to be the second most lucrative segment in the global companion animal vaccines market, with an attractiveness index of 1.1 during the forecast period.

Market consolidation in developed regions could ease product availability

Mergers and acquisitions are gaining a wider footprint within the global companion animal vaccines market in developed regions, which is expected to widen product availability and ease market access. For example, global veterinary product manufacturer Elanco has agreed to buy Boehringer Ingelheim Vetmedica Inc.'s U.S. companion animal vaccines business apart from Fort Dodge manufacturing facility as of October 2016. Besides strengthening Elanco's market position in the global animal health business, the company also plans to boost vaccine research and testing in collaboration with veterinarians.

"Rising adoption of pets is fuelling the global companion animal vaccines market

Download the full report: https://www.reportbuyer.com/product/4833633/

About Reportbuyer
Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers
http://www.reportbuyer.com

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: query@reportbuyer.com
Tel: +44 208 816 85 48
Website: www.reportbuyer.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/companion-animal-vaccines-market-canine-segment-anticipated-to-retain-its-dominance-throughout-the-forecast-period-global-industry-analysis-and-opportunity-assessment-2016-2026-300442202.html


'/>"/>
SOURCE ReportBuyer
Copyright©2017 PR Newswire.
All rights reserved


Related medicine technology :

1. QIAGEN Expands Pipeline of Promising New Biomarkers for Development of Personalized Healthcare Companion Diagnostics
2. Companion 2 Hospital Driver for Powering SynCardia Total Artificial Heart Wins Silver at Medical Design Excellence Awards
3. Companion Diagnostics Market, 2012-2023
4. Companion Diagnostics Market Report - Streamlining Drug Development and Advancing Personalized Medicine
5. Ventana receives approval from Chinas FDA for first fully automated IHC companion diagnostic identifying ALK protein expression in lung cancer patients
6. Harrisvaccines, Inc. Secures Exclusive Rights From AlphaVax, Inc. to Develop RNA Particle Vaccines for All Diseases in Companion Animals
7. Kennel Cough is in Season all Year for our Canine Companions
8. Ventana to partner with Incyte on the development of Companion Diagnostic tests
9. Ventana announces HER2 companion diagnostic to identify breast cancer patients for Roches latest targeted medicines, Perjeta and Kadcyla
10. Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment
11. QIAGEN and AstraZeneca Collaborate to Develop Liquid Biopsy-Based Companion Diagnostic to Advance EGFR Mutation Profiling in Lung Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/9/2017)... JERUSALEM , May 9, 2017  Oramed ... www.oramed.com ), a clinical-stage pharmaceutical company focused on ... today that the Canadian Intellectual Property Office has ... for Oral Administration of Exenatide". The patent covers ... analog. GLP-1 is an incretin hormone ...
(Date:5/6/2017)... , May 5, 2017   Provista , a proven ... than 200,000 customers, today announced Jim Cunniff as ... of executive and business experience to Provista, including most recently ... in California . He assumed his new ... is a great fit for Provista," says Jody Hatcher ...
(Date:5/4/2017)... Tenn. , May 4, 2017  A ... Infection Control, Ultraviolet-C light as a ... Tru-D SmartUVC,s ability to reduce bioburden on anesthesia ... bioburden reduction on high-touch, complex medical equipment surfaces ... surgical infections. "This study further validates ...
Breaking Medicine Technology:
(Date:5/19/2017)... (PRWEB) , ... May 19, 2017 , ... In a ... PlushBeds , a luxury online mattress company that specializes in natural and organic ... nation’s leading grassroots autism organization) for every unique share their recent viral Facebook ...
(Date:5/19/2017)... ... May 19, 2017 , ... DMG Productions is ... of Innovations with Ed Begley, Jr., airing fourth quarter 2017 on FOX Business. ... clean, organic dietary supplement made from naturally occurring ingredients. Innovations will enlighten viewers ...
(Date:5/19/2017)... ... 2017 , ... Springfield, Vermont-based law firm of Brady/Callahan has released a new ... Hire An Experienced Personal Injury Attorney, " the article offers insight for people who ... article says. if someone is injured due to another person's negligence, they ...
(Date:5/19/2017)... ... May 19, 2017 , ... The ... planning assistance to families and business owners in the region, is embarking on ... MS sufferers and their families. , Multiple sclerosis (MS) is a demyelinating disease ...
(Date:5/19/2017)... Reston, VA (PRWEB) , ... May 19, 2017 ... ... mobile application containerization, today announced a sponsorship and speaking session at the 7th ... Exchange is the longest-running hosted enterprise mobility and digital transformation conference whose expressed ...
Breaking Medicine News(10 mins):